Substance / Medication

Triiodothyronine

Overview

Active Ingredient
liothyronine
RxNorm CUI
10814

Indications

® NP Thyroidtablets (thyroid tablets, USP) are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of th

Labeler: Acella Pharmaceuticals, LLCUpdated: 2026-01-27T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

Drugs with thyroid hormone activity, alone or together with other therapeutic agents, have been used for the treatment of obesity. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threaten

Contraindications

When this intervention should not be used

Thyroid hormone preparations are generally contraindicated in patients with diagnosed but as yet uncorrected adrenal cortical insufficiency, untreated thyrotoxicosis, and apparent hypersensitivity to any of their active or extraneous constituents. There is no well-documented evidence from the litera

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

3 trials linked to this intervention

3
Total Trials
0
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Triiodothyronine Supplementation for Children Undergoing Cardiopulmonary Bypass: A Meta-Analysis.
Radman Monique R, Slee April E, Marwali Eva M et al. · Pediatr Cardiol · 2024
PMID: 38530419Meta-Analysis
Low triiodothyronine (T3) levels predict worse outcomes in autoimmune encephalitis-A meta-analysis of current literature.
Rehan Syeda Tayyaba, Ul Hussain Hassan, Ali Eman et al. · Brain Behav · 2024
PMID: 38898639Meta-AnalysisFull text (PMC)
Free triiodothyronine and free thyroxine hormone levels in relation to breast cancer risk: a meta-analysis.
Lei Zhengwu, Zeng Bin, Wu Lina et al. · Endokrynol Pol · 2022
PMID: 35381094Meta-Analysis
Benefits and Harms of Levothyroxine/L-Triiodothyronine Versus Levothyroxine Monotherapy for Adult Patients with Hypothyroidism: Systematic Review and Meta-Analysis.
Millan-Alanis Juan Manuel, González-González José Gerardo, Flores-Rodríguez Andrea et al. · Thyroid · 2021
PMID: 34340589Meta-AnalysisFull text (PMC)
Thyroid Hormone (Triiodothyronine) Therapy in Children After Congenital Heart Surgery: A Meta-Analysis.
Flores Saul, Loomba Rohit S, Checchia Paul A et al. · Semin Thorac Cardiovasc Surg · 2020
PMID: 31128253Meta-Analysis
Genome-wide meta-analysis identifies novel loci associated with free triiodothyronine and thyroid-stimulating hormone.
Popović M, Matana A, Torlak V et al. · J Endocrinol Invest · 2019
PMID: 30843173Meta-Analysis
Thyroxine alone or thyroxine plus triiodothyronine replacement therapy for hypothyroidism.
Ma Chao, Xie Jiawei, Huang Xia et al. · Nucl Med Commun · 2009
PMID: 19491714Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Liothyronine (substance)
SNOMED CT
61275002
UMLS CUI
C0041014
RxNorm CUI
10814
Labeler
Acella Pharmaceuticals, LLC

Clinical Data

This intervention maps to 7 entities in the Healos knowledge graph.

6
Conditions
1
Biomarkers
0
Specialists
0
Symptoms
3
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.